Clopidogrel
- Product Name
- Clopidogrel
- CAS No.
- 113665-84-2
- Chemical Name
- Clopidogrel
- Synonyms
- methyl (2s)-2-(2-chlorophenyl)-2-(9-thia-4-azabicyclo[4.3.0]nona-7,10-dien-4-yl)acetate;CLOPIDOGREL;Chlopidogrel;ClopidogrelHcl;Clopidogrel–d4;(S)-Clopidogrel;Clopidogrel-13C3;Clopidogrel Pellets;Clopidogrel Free base;Clopidogrel USP/EP/BP
- CBNumber
- CB3341209
- Molecular Formula
- C16 H16 Cl N O2 S
- Formula Weight
- 321.82
- MOL File
- 113665-84-2.mol
Clopidogrel Property
- alpha
- D20 +51.52° (c = 1.61 in methanol)
- Boiling point:
- 423.7±45.0 °C(Predicted)
- Density
- 1.317±0.06 g/cm3(Predicted)
- storage temp.
- 2-8°C
- pka
- 4.56±0.20(Predicted)
- CAS DataBase Reference
- 113665-84-2(CAS DataBase Reference)
Safety
- Hazard Codes
- Xn
- Risk Statements
- 22-36/37/38
- Safety Statements
- 26-36
- Hazardous Substances Data
- 113665-84-2(Hazardous Substances Data)
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H302Harmful if swallowed
H315Causes skin irritation
H319Causes serious eye irritation
H335May cause respiratory irritation
- Precautionary statements
-
P261Avoid breathing dust/fume/gas/mist/vapours/spray.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
N-Bromosuccinimide Price
- Product number
- CS-0656
- Product name
- Clopidogrel
- Purity
- 99.57%
- Packaging
- 100mg
- Price
- $50
- Updated
- 2021/12/16
- Product number
- API0002073
- Product name
- CLOPIDOGREL
- Purity
- 95.00%
- Packaging
- 1G
- Price
- $179.55
- Updated
- 2021/12/16
- Product number
- orb134722
- Product name
- Clopidogrel
- Purity
- >99%
- Packaging
- 1g
- Price
- $606.9
- Updated
- 2021/12/16
- Product number
- CD33897
- Product name
- Clopidogrel-13C-d4HCl
- Packaging
- 1mg
- Price
- $725
- Updated
- 2021/12/16
- Product number
- C-7730
- Product name
- ClopidogrelLabeledd4
- Packaging
- 10mg
- Price
- $1450
- Updated
- 2021/12/16
Clopidogrel Chemical Properties,Usage,Production
Description
Clopidogrel was launched in the US as a potent inhibitor of platelet aggregation for the preventive management of secondary ischemic events, including MI, stroke and vascular deaths. Clopidogrel can be synthesized in 4 steps (including an optical resolution to the S active enantiomer) from 2-(2- ch1orophenyl)-glycine, the key step being the cyclization to thienopyridine with formaldehyde and acetic acid. Clopidogrel belongs to the original chemical class of Ticlopidine, but shows fewer side effects (in particular, bone-marrowsuppressing effects) at the dosage generally used. Like Ticlopidine, it is an Adenosine diphosphate (ADP) antagonist acting at the purinergic P2y receptor. In in vivo experiments with rabbits, Clopidogrel shows a maximal antiaggregant effect at 20mg/kg po, reducing adhesion of platelets to the vascular subendothelium ; moreover, it reduces myointimal thickening occuring after endothelial injury of rat carotid artery. Clopigrel does not affect platelet aggregation in vitro ; actually, its in vivo activity is highly dependent on hepatic metabolism. The results of a CAPRIE trial (Clopidogrel versus Aspirin in patients at risk of ischemic events) demonstrated that Clopidogrel was well tolerated and more effective than aspirin.
Originator
Sanofi (France)
Uses
anthelmintic, antiparasitic, antimite
Uses
Sertraline metabolite
brand name
Plavix (Sanofi Aventis);Plavix, Iscover.
General Description
Clopidogrel, methyl (+)-(S)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate sulfate (Plavix), is useful for the preventativemanagement of secondary ischemic events, including myocardialinfarction, stroke, and vascular deaths. It may beclassified as a thienopyridine because of its heterocyclicsystem. Several agents possessing this system have beenevaluated as potential antithrombotic agents. These agentshave a unique mechanism, in that they inhibit the purinergicreceptor located on platelets. Normally, nucleotides act asagonists on these receptors, which include the P2Y type.Two P2Y receptor subtypes (P2Y1 and P2Y2) found onplatelets, when stimulated by adenosine diphosphate (ADP),cause platelet aggregation.
Clinical Use
Clopidogrel acts as an antagonistto the P2Y2 receptor. It is probably a prodrug that requiresmetabolic activation, because in vitro studies do not interferewith platelet aggregation. Although platelet aggregationis not normally seen in the first 8 to 11 days after administrationto a patient, the effect lasts for several days after thedrug therapy is discontinued. Unlike other thienopyridinescurrently used, clopidogrel does not seriously reduce thenumber of white cells in the blood, and therefore, routinemonitoring of the white blood cell count is not necessaryduring treatment.
Drug interactions
Potentially hazardous interactions with other drugs
Antibacterials: antiplatelet effect possibly reduced by
erythromycin.
Anticoagulants: enhanced anticoagulant effect with
coumarins and phenindione; manufacturer advises to
avoid with warfarin.
Heparin: increased risk of bleeding.
Antidepressants: antiplatelet effect possibly reduced
by fluoxetine, fluvoxamine and moclobemide.
Anti-diabetics: avoid with repaglinide if possible due
to increased repaglinide exposure.
Antiepileptics: antiplatelet effect possibly reduced by
carbamazepine and oxcarbazepine.
Antifungals: antiplatelet effect possibly reduced
by fluconazole, itraconazole, ketoconazole and
voriconazole.
Antivirals: antiplatelet effect possibly reduced by
etravirine.
Statins: concentration of rosuvastatin increased,
maximum rosuvastatin dose is 20 mg.
Ulcer healing drugs: antiplatelet effect possibly
reduced by cimetidine, lansoprazole, pantoprazole
and rabeprazole; antiplatelet effect reduced by
omeprazole and esomeprazole - avoid concomitant
use if possible.
Metabolism
Clopidogrel is a prodrug and is extensively metabolised in
the liver, mainly to the inactive carboxylic acid derivative;
metabolism is mediated by cytochrome P450 isoenzymes
including CYP3A4 and CYP2B6, CYP1A2, CYP1A1,
and CYP2C19. The active metabolite appears to be a
thiol derivative
Clopidogrel and its metabolites are excreted in urine and
in faeces; about 50% of an oral dose is recovered from the
urine and about 46% from the faeces.
Clopidogrel Preparation Products And Raw materials
Raw materials
Preparation Products
Clopidogrel Suppliers
- Tel
- 021-51111890 15317326293
- sales@molnova.com
- Country
- China
- ProdList
- 4195
- Advantage
- 58
- Tel
- +86-817-5586080
- Fax
- +86-817-5527378
- Country
- China
- ProdList
- 42
- Advantage
- 69
- Tel
- 821-50328103-801 18930552037
- Fax
- 86-21-50328109
- 3bsc@sina.com
- Country
- China
- ProdList
- 15861
- Advantage
- 69
- Tel
- 021-20908456
- Fax
- 021-58180499
- sales@BioChemBest.com
- Country
- China
- ProdList
- 6005
- Advantage
- 61
- Tel
- 13817811078
- Fax
- 86-021-50426522,50426273
- sales@jingyan-chemical.com
- Country
- China
- ProdList
- 9986
- Advantage
- 60
- Tel
- 1-(800)-881-8210
- Fax
- 615-250-9817
- inquiries@lgmpharma.com
- Country
- United States
- ProdList
- 2127
- Advantage
- 70
- Tel
- 021-58099652-8005 13585536065
- Fax
- 021-58099609
- bin.wu@shlschem.com
- Country
- China
- ProdList
- 9816
- Advantage
- 59
- Tel
- 025-83697070
- Fax
- +86-25-83453306
- info@chemlin.com.cn
- Country
- China
- ProdList
- 19957
- Advantage
- 64
- Tel
- 021-54308259
- info@hanhongsci.com
- Country
- China
- ProdList
- 43010
- Advantage
- 64
- Tel
- +86-512-66319723
- Fax
- +86-512-68090175
- Country
- China
- ProdList
- 110
- Advantage
- 67
View Lastest Price from Clopidogrel manufacturers
- Product
- Clopidogrel 113665-84-2
- Price
- US $100.00/g
- Min. Order
- 25g
- Purity
- 99%
- Supply Ability
- 1000g
- Release date
- 2023-03-10
- Product
- Clopidogrel 113665-84-2
- Price
- US $200.00/kg
- Min. Order
- 1kg
- Purity
- 99%
- Supply Ability
- 1000kg/Month
- Release date
- 2022-11-23
- Product
- Clopidogrel 113665-84-2
- Price
- US $1.00-1.00/KG
- Min. Order
- 1g
- Purity
- 99%
- Supply Ability
- 50tons
- Release date
- 2020-05-09